Epigenetic Mechanisms and Therapeutic Perspectives for Neurodevelopmental Disorders
AbstractThe number of children with mild neurodevelopmental disorders, such as autism, has been recently increasing in advanced countries. This increase is probably caused by environmental factors rather than genetic factors, because it is unlikely that genetic mutation rates suddenly increased within a short period. Epigenetics is a mechanism that regulates gene expression, depending not on the underlying DNA sequence but on the chemical modifications of DNA and histone proteins. Because mental stress can alter the epigenetic status in neuronal cells, environmental factors may alter brain function through epigenetic changes. However, one advantage of epigenetic changes is their reversibility. Therefore, diseases due to abnormal epigenetic regulation are theoretically treatable. In fact, several drugs for treating mental diseases are known to have restoring effects on aberrant epigenetic statuses, and a novel therapeutic strategy targeting gene has been developed. In this review, we discuss epigenetic mechanisms of congenital and acquired neurodevelopmental disorders, drugs with epigenetic effects, novel therapeutic strategies for epigenetic diseases, and future perspectives in epigenetic medicine. View Full-Text
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Kubota, T.; Takae, H.; Miyake, K. Epigenetic Mechanisms and Therapeutic Perspectives for Neurodevelopmental Disorders. Pharmaceuticals 2012, 5, 369-383.
Kubota T, Takae H, Miyake K. Epigenetic Mechanisms and Therapeutic Perspectives for Neurodevelopmental Disorders. Pharmaceuticals. 2012; 5(4):369-383.Chicago/Turabian Style
Kubota, Takeo; Takae, Hirasawa; Miyake, Kunio. 2012. "Epigenetic Mechanisms and Therapeutic Perspectives for Neurodevelopmental Disorders." Pharmaceuticals 5, no. 4: 369-383.